Results 171 to 180 of about 39,064 (303)
Biosimilar, biobetter and next generation therapeutic antibodies [PDF]
, 2011 Alain Beck
openalex +1 more source
Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. [PDF]
, 2019 BACKGROUND AND AIMS:Treatment pathways for ulcerative colitis (UC) and Crohn's disease (CD) are shifting to a more individualized, risk-stratified approach.
Cao, Charlie +5 more
core
Biotechnology and Bioengineering, Volume 122, Issue 7, Page 1710-1723, July 2025.This study investigates the temporal effects of galactose and manganese on the N‐glycosylation of Trastuzumab (mAb) antibody during fed‐batch and perfusion bioprocessing modes to reveal the influence of feeding schedules on mAb N‐glycosylation patterns. These findings will aid in building process control schemes for mAb bioprocessing.
Aron Gyorgypal +4 more
wiley +1 more source
The approaches to the assessment of biosimilarity of biotechnological preparations: quality issues
Регуляторные исследования и экспертиза лекарственных средств, 2018 Due to expiration of patents for most highly demanded biotechnological preparations there is a tendency for the increase in the number of applications for marketing authorisation of biosimilar preparations (biosimilars).
A. N. Mironov +8 more
doaj
Worldwide experience with biosimilar development [PDF]
, 2011 Mark McCamish, Gillian R. Woollett
openalex +1 more source
Cancer Medicine, Volume 14, Issue 14, July 2025.ABSTRACT Background Immunotherapy combined with chemotherapy has become the standard treatment for HER2‐negative gastric cancer (GC), but its clinical benefits remain limited, with a median progression‐free survival (mPFS) of 6–8 months and median overall survival (mOS) of 15–18 months. These outcomes are particularly poor in patients with CPS < 1. The
Wenke Li +8 more
wiley +1 more source
The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 895-908, July 2025.Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley +1 more source
Biosimilars: Are They Ready for Primetime in the United States? [PDF]
, 2011 Bradford R. Hirsch, Gary H. Lyman
openalex +1 more source
Friction and Wear Characterizations in Electrospun Nanofibrous Scaffolds for Cartilage Engineering
Nano Select, Volume 6, Issue 7, July 2025.Articular cartilage (AC)‐engineered electrospun scaffolds have experienced a surge in interest in publication in recent years. However, nanofiber frictional properties are poorly explored in the existing literature. We evaluated the effect of countersurface, speed, and hydrophilicity on nanofibers.
André Mathias Souza Plath +2 more
wiley +1 more source
Treatment Landscape in Pediatric Immune Thrombocytopenia: Addressing Unmet Needs
Pediatric Blood &Cancer, Volume 72, Issue 7, July 2025.ABSTRACT Pediatric immune thrombocytopenia (ITP) is associated with a multifaceted burden on children and their parents/caregivers due to bleeding, fatigue, activity restrictions, and psychological distress. Most children recover within 12 months, but up to 30% develop chronic ITP.
Joana Azevedo +4 more
wiley +1 more source